Tirzepatide 1.25 mg: the dose that starts your treatment

Why does 1.25 mg tirzepatide appear in searches if it isn't a real dose?

This is a question our prescribers hear fairly often. The short answer is that 1.25 mg tirzepatide has appeared in early-phase research literature and some overseas compounding contexts, which is enough to seed a search trend. In the UK, Mounjaro (the licensed brand name for tirzepatide) comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. Each is delivered as a pre-filled KwikPen containing four weekly doses. There is no 1.25 mg pen, and no 1.25 mg tirzepatide product is authorised by the MHRA for use in the UK.

Some patients wonder whether they could inject half a dose from a 2.5 mg pen to ease into treatment more gently. The pen is not designed for partial doses. The KwikPen's delivery mechanism is calibrated for a single weekly administration; attempting to split it risks an inaccurate amount of medicine, potential needle contamination and a damaged device. The NHS tirzepatide medicine page is clear that you should use each dose as instructed and never attempt to alter it yourself.

If you're finding the starting dose difficult to tolerate, that conversation belongs with your prescriber, who has clinical options available, including extending the time at 2.5 mg before any increase. You can also find a detailed explanation of why 1.25 mg Mounjaro is not a licensed option and what that means for anyone who has come across it online.

What is the 2.5 mg starting dose actually for?

The first pen of Mounjaro exists to settle your system, not to produce weight loss. Tirzepatide activates both GLP-1 and GIP receptors, which slows how quickly food leaves your stomach and reduces appetite signalling. Starting at 2.5 mg limits the gastrointestinal effects (nausea, loose stools, heartburn) that tend to be most noticeable when the medicine is new to your body. Most people find these effects ease within the first couple of weeks.

After four weeks at 2.5 mg, the next step in the licensed schedule is 5 mg. You can read more about what to expect at the 5 mg stage and how that transition typically feels. The titration then continues at roughly four-week intervals, guided by your clinical team, up to the highest dose you tolerate well. Trial data from SURMOUNT-1, published in the New England Journal of Medicine, showed average body-weight reductions of around 20–21% at the 15 mg maintenance dose over 72 weeks, though what matters clinically is what you tolerate and respond to, not reaching the maximum.

People sometimes look at whether meaningful weight loss is possible at very low doses. The honest answer is that 2.5 mg is a dose calibration step; meaningful loss typically builds as the dose increases over the following months.

Is there any situation where a lower dose might be appropriate?

Occasionally, patients who experience significant side effects at 2.5 mg ask whether a lower dose could be a temporary solution. In practice, prescribers have a few legitimate tools: they can extend the time spent at 2.5 mg, adjust meal timing and composition to reduce nausea, or in some circumstances consider whether this medicine is the right fit at all. What they cannot do is prescribe a 1.25 mg dose that does not exist in the licensed supply chain.

The question of whether a sub-2.5 mg dose would even be effective is largely unanswered in peer-reviewed evidence for this medicine. The SURMOUNT programme was built around the licensed schedule. Compounded or altered doses sit outside that evidence base entirely.

If you've seen references to 1.25 mg tirzepatide dose from compounding pharmacies (often based in the US) it's worth knowing that compounded tirzepatide products are not authorised in the UK, and the MHRA has warned about medicines sourced outside the licensed UK supply chain. Any seller offering tirzepatide without a UK prescription from a regulated prescriber is a red flag, not a bargain.

The broader picture of how Mounjaro works across its full dose range, including the evidence base and eligibility criteria, is covered on the Mounjaro information page. For context on the private cost of treatment, the weight-loss treatments overview sets out what a legitimate private prescription includes. Worth reading before you compare prices.

How does a prescriber decide when to move beyond 2.5 mg?

The decision to increase from 2.5 mg to 5 mg (and from each subsequent dose to the next) rests entirely with your prescriber, based on how you're tolerating the current dose and what your progress looks like. At a regulated service like ours, that review happens before every repeat order. A real clinician reads your responses, not software.

There's no rule that you must reach 15 mg. Some patients settle at 5 mg or 7.5 mg and find it sufficient; others need higher doses to see meaningful progress. The 5 mg Mounjaro page explains how most people experience that dose as the first genuinely therapeutic step. Your prescriber factors in side-effect history, weight trajectory and your wider health picture at each review.

If you've already started Mounjaro elsewhere and are transferring to a new provider, current dose evidence is part of the clinical review process. That protects you, a prescriber approving a dose increase without checking your history isn't doing their job properly. Our clinical team, including lead prescriber Mostafa Damghani, applies this review at every stage. If you have questions about eligibility or how the process works end to end, our FAQ page covers the most common ones, or you can get in touch directly.